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Necroptosis ismediated by engagement of RIP kinases and a downstreampseudokinase,MLKL. In this issue
of Immunity, Murphy et al. (2013) show that it operates at or close to the final execution mechanism of the
death process.‘‘Fa, fa, fa, fa, fa, fa, fa, fa, fa, fa’’
—David ByrneActive cell death, the phenomenon
where a cell responds to signals by
engaging molecular pathways that lead
to its demise, is best known as the pro-
cess of apoptosis, in which caspases
orchestrate the cell’s quietus. In the past
decade, however, we have realized that
there are other, nonapoptotic forms of
active cellular suicide, including an
intriguing and potentially important pro-
cess of regulated necrosis called nec-
roptosis. Although caspases act as the
‘‘executioners’’ of apoptosis, the mole-
cules involved in actually killing a cell
that dies by necroptosis have been
elusive. In this issue of Immunity, we
move a step closer to unmasking this
killer, a pseudokinase, that hides behind
the moniker mixed lineage kinase-like
(MLKL) (Murphy et al., 2013).
Necroptosis is best known as a
response to ligation of a death receptor,
one of a subset of members of the tumor
necrosis factor receptor family, including
TNFR1. It can also be engaged by cell
surface Toll-like receptors that engage
the signaling molecule TRIF (Kaczmarek
et al., 2013). In both cases, and in striking
contrast to apoptosis, necroptosis occurs
when such signals are paired with inhibi-
tion or ablation of a caspase (caspase-
8). This is because caspase-8, in the
form of a heterodimer with another cas-
pase-8-like molecule, c-FLIPL, actively
antagonizes the signals that trigger
necroptosis (Green et al., 2011). These
include two kinases, receptor interacting
protein kinase 1 and 3 (RIPK1 and
RIPK3), both of which are activated in
the process and form an amyloid struc-
ture upstream of the final death knoll.
The kinase activity of both RIPK1 andRIPK3 are required for necroptosis, and
inhibition of RIPK1 with an inhibitor
(necrostatin) blocks the process. In turn,
RIPK3 then phosphorylates MLKL, which
is required for the ensuing necrotic death
(see Figure 1; Sun et al., 2012; Zhao et al.,
2012). The requisite role of MLKL in nec-
roptosis is clearly indicated by ablation
of the gene in mice, as shown by Murphy
et al. (2013) and another study (Wu et al.,
2013), and like RIPK3 ablation, the ani-
mals show no developmental or homeo-
static phenotype in the absence of overt
stress but lack cell death induced by
TNF plus caspase inhibitor.
Necroptosis has been implicated in
several pathological processes, including
ischemia or reperfusion injury of brain,
heart, and kidney, as well as pancreatitis,
based on animal models in wild-type
versus RIPK3-deficient mice. With the
availability of MLKL-deficient animals, it
will now be possible to further explore
pathologies that may be associated with
necroptosis, and indeed MLKL-deficient
animals were resistant to pancreatitis
induced by cerulean (Wu et al., 2013). As
definitive roles for MLKL in pathology are
revealed, effective inhibitors of its func-
tion would be of value as therapeutics.
Although such therapeutics are not yet
available, the identification of necrosulfo-
namide as an MLKL inhibitor (Sun et al.,
2012) provides evidence that MLKL func-
tion is, in principle, drug-able.
By sequence homology, MLKL is a
member of the TKL family of kinases, but
although it conserves the ATP-binding
VAIK motif (and binds ATP), it lacks the
DFG and HRD domains needed for catal-
ysis and is therefore a pseudokinase
(Boudeau et al., 2006). Pseudokinases
are known to have a number of functions,
acting as partners or scaffolds for regu-
lation (positive or negative) of bona fide
kinases, phosphatases, histone acetyl-Immunity 39, Setransferases, transcription factors, and
other functions. Among the pseudoki-
nases, MLKL is most closely related to
IRAK2 (Boudeau et al., 2006), which par-
ticipates in TLR signaling to NF-kB.
Intriguingly, it is also phylogenically
related to the RIP kinases, including
RIPK1 and RIPK3. RIPK1, in addition to
its kinase-dependent function in necrop-
tosis, also has a kinase-independent
scaffolding function that, similarly to
IRAK2, promotes TLR- and TNFR1-medi-
ated NF-kB activation.
Murphy et al. (2013) resolved the struc-
ture of MLKL and found a critical interac-
tion between K219 of the VAIK motif and
Q343 in the activation domain where there
are also three phospho-sites targeted by
RIPK3. In contrast, in kinases, the corre-
sponding lysine normally associates with
what would be E239 in MLKL. The K-Q
interaction is highly conserved in MLKL
from different species (as K-Q or K-E),
although in lemurs there is an E219-
K343 ‘‘swap,’’ altogether suggesting that
this hydrogen bond interaction is critically
important for MLKL function. Strikingly,
they found that the mutation K219M
results in an MLKL protein that directly
causes necrosis, even in cells lacking
RIPK3. They suggest that RIPK3 phos-
phorylation of MLKL promotes dissocia-
tion of K219-Q343 to activate the prone-
croptotic function of MLKL (Figure 1,
inset). If so, then MLKL is likely to be the
downstream effector of RIPK3 in the
death process and may well act as more
than a regulator of RIPK3 and perhaps
more than scaffold.
What then, does ‘‘activated’’ MLKL
do to promote necroptosis? Although
studies have implicated reactive oxygen,
elevated metabolism, or other unknown
effects involving mitochondria (Green
et al., 2011), a definitive demonstration
that one or more of these represent theptember 19, 2013 ª2013 Elsevier Inc. 421
Figure 1. MLKL Acts Downstream of RIPK3 in Necroptosis
Ligation of death receptors or cell surface TLRs (via the adaptor TRIF) engage RIPK1, which then forms an
amyloid-like complex with RIPK3. RIPK1 also recruits FADD, cFLIPL (FLIP), and caspase-8; the protease
activity of the complex prevents necroptosis. Disruption or blockade of the protease activity allows the
formation of the RIPK3 necrosome, which then phosphorylates MLKL. This probably induces MLKL
‘‘activation’’ via disruption of the K219-Q343 interaction in the pseudokinase domain. Active MLKL then
promotes necroptosis and possibly other inflammatory events. (The author thanks T. Moldoveanu, who
assisted with the image of the MLKL structure.)
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Previewsexecutioner for this form of death is lack-
ing. Similarly, the mitochondrial fission
protein DRP1 and the mitochondrial outer
membrane protein PGAM5 have been
proposed as agents of necroptosis
(Wang et al., 2012), but again neither
definitive proof of their involvement nor
a mechanism whereby they cause cell
death has been described. Murphy et al.
(2013) failed to observe an effect of
silencing PGAM5, and although this
cannot be taken as evidence that it is
not involved in necroptosis, it precluded
further explorations of its function in this
study. Although MLKL binds to ATP, it
cannot hydrolize it, and mutation of the
binding site to ablate ATP binding did
not destroy the pronecroptotic function
of this molecule. At this point, the final
effector of necroptosis downstream of
MLKL has been elusive. We know that
cells die in an active manner, and we
know that RIPK3-phosphorylated MLKL
functions in the process, but we do not
know what ultimately kills the cell.
Further, we do not even know whether
the primary function of MLKL activation
by RIPK3 is the execution of cell death,422 Immunity 39, September 19, 2013 ª2013per se. It is axiomatic that such a pathway
as this did not evolve as a mechanism
to promote organismal diseases such
as ischemia and reperfusion injury (obvi-
ously, sucha functioncannot beselected).
However, active cell death is a funda-
mental strategy for a multicellular organ-
ism to resist intracellular infection; cells
die prior to replication of the parasite,
and indeed, necroptosis has been impli-
cated in defense against some viruses.
Perhaps not surprisingly, then, activation
of RIPK3 is associated with inflammatory
responses (Kaczmarek et al., 2013), and
in one case the response has been shown
tobedependent onMLKLbut possibly not
cell death (Kang et al., 2013). Necroptosis
might then be somewhat analogous to
the cell death process of pyroptosis,
where caspase activation both performs
proinflammatory cytokine production and
orchestrates the death of the cell.
Nevertheless, the finding that the
mutant MLKL K219M protein kills cells
independently of RIPK3 raises an in-
triguing question: might there be kinases
other than RIPK3 capable of phosphory-
lating and ‘‘activating’’ MLKL to promoteElsevier Inc.necrosis? A survey of RIPK3 phospho-tar-
gets suggests that the specificity of the
kinase is similar to that of MAP kinases
(Wu et al., 2012), and therefore it is not
ridiculous to think that a kinase with this
specificity may in some cases activate
the cell death function of MLKL. In this
regard it is interesting that Jun-kinase
(JNK) has long been associated with cell
death, although the mechanisms have
been obscure. That said, it is clear that
JNK does not substitute for RIPK3 in nec-
roptosis induced by TNFR or TLR ligation,
and therefore a role for JNK in MLKL acti-
vation is, at best, a long shot. But in any
case, if MLKL can mediate necrotic death
independently of the RIP kinases, we may
have to modify our definitions of necrop-
tosis (perhaps as ‘‘necrotic cell death
dependent on MLKL’’?) and may well
find that its roles in health and disease
are even more extensive than currently
thought. David Byrne once imagined a
deranged murderer who felt he was
launching into glory (‘‘Je me lance, vers
la gloire’’). We have seen the face of
MLKL, and while its function remains a
mystery, we are coming to know, and will
someday cage, this killer.REFERENCES
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